HELSINKI, Oct. 29, 2024 /PRNewswire/ — TrueMed, a leading provider of anti-counterfeiting technology solutions, is proud to announce its new partnership with a Top 10 global pharmaceutical company to bolster the integrity of its medications. This strategic collaboration will harness TrueMed’s cutting-edge AI technology to protect patients from the growing threat of counterfeit and illicit medicines, while also enhancing the pharmaceutical company’s field authentication and forensic capabilities.
As counterfeit pharmaceutical volumes rise, and security professionals face increasing challenges in authenticating diverse types of packaging across various field environments, this partnership addresses critical needs. By leveraging TrueMed’s AI-powered platform, the pharmaceutical company significantly reduces reaction times during investigations, improves authentication accuracy in the field, and gathers critical forensic intelligence to support enforcement actions.
TrueMed’s AI technology uses mobile phone cameras, machine learning, and data analytics to quickly analyze packaging, identifying counterfeit drugs and verifying authenticity in seconds.
Jyrki Berg, CEO of TrueMed, remarks, “This partnership brings real change. By applying our forensic capabilities, we’re improving how counterfeit drug analysis is done, helping to make the pharmaceutical supply chain safer and more dependable.”
For more information about TrueMed’s advanced AI-counterfeit detection solutions, please visit www.truemedinc.com.
About TrueMed
TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential illicit products, allowing companies to quickly and efficiently protect their brands and their customers.
For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, 385565@email4pr.com, +358 50 568 0782
SOURCE TrueMed
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL…
More than 50% of men now face erectile dysfunction after the age of 40. In…
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025)…
After six months of research on the ingredients and thousands of feedback from real consumers,…
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT InterventionsSOUTH SAN FRANCISCO, Calif.,…
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
